Global Blood Therapeutics Company Profile (NASDAQ:GBT)

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its earnings results on Monday, August, 7th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.06. During the same period in the previous year, the firm earned ($0.58) earnings per share. View Global Blood Therapeutics' Earnings History.

12 brokers have issued 12-month target prices for Global Blood Therapeutics' stock. Their forecasts range from $23.05 to $83.00. On average, they expect Global Blood Therapeutics' share price to reach $52.91 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

• 1. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
• 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/16/2017)
• 3. Cantor Fitzgerald analysts commented, "We are initiating coverage on Global Blood Therapeutics (GBT) with an Overweight rating and a $61/share price target. We believe Global Blood's lead candidate, GBT440, has demonstrated compelling potential for the treatment of sickle cell disease (SCD), based on its reported clinical efficacy and safety data. Moreover, we believe the mechanism of action of oxygen affinity modulation is strongly validated in the scientific literature. Sickle cell disease remains a therapeutic area with a significant unmet need, for which the only approved therapy demonstrating clinical benefit is carcinogenic. Global Blood is currently enrolling up to 400 patients with SCD in its Phase 3 study." (3/15/2017)
• 4. J P Morgan Chase & Co analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)
• 5. Instinet analysts commented, "We are initiating coverage of GBT with a Buy rating and $50 price target. We view GBT shares as attractively valued following selloffs in 2016 and expect additional data in 2017 to yield upside by providing further clarity on GBT440's safety and efficacy profile. Specifically, we anticipate upside to GBT shares following a positive readout from the biomarker-driven Phase 2 trials of GBT440 in patients with IPF in 2H17. We expect renewed interest in this readout and the timing of this readout to alleviate the perception that shares are 'dead money' between now and GBT's final Phase 3 read-out in SCD in 1H19. We believe that data from IPF together with updates from the extension studies in SCD will further support GBT440's mechanism of action, better framing the risk around the primary share driver, Phase 3 readout in SCD. The opportunity for IPF remains $16 per share upside to our $50 target price." (3/1/2017)

Some companies that are related to Global Blood Therapeutics include Ironwood Pharmaceuticals (IRWD), Intrexon Corporation (XON), Blueprint Medicines Corporation (BPMC), Foundation Medicine (FMI), Medpace Holdings (MEDP), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Esperion Therapeutics (ESPR), Immunomedics (IMMU), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Arena Pharmaceuticals (ARNA), Cellectis S.A. (CLLS), Crispr Theraptc (CRSP), Spectrum Pharmaceuticals (SPPI) and Editas Medicine (EDIT).

Global Blood Therapeutics' management team includes the folowing people:

• Ted W. Love M.D., President, Chief Executive Officer, Director
• Jeffrey S. Farrow, Chief Financial Officer
• Peter Radovich, Senior Vice President, Operations
• Hing L. Sham, Senior Vice President, Research
• Jung E. Choi, Chief Business and Strategy Officer
• Tricia Borga Suvari Esq., Chief Legal Officer
• Charles J. Homcy M.D., Director
• Willie L. Brown Jr, Independent Director
• Scott W. Morrison, Independent Director
• Deval L. Patrick, Independent Director

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (12.36%), BlackRock Inc. (7.81%), Vanguard Group Inc. (6.73%), State Street Corp (4.90%), Janus Henderson Group PLC (2.25%) and Redmile Group LLC (1.45%). Company insiders that own Global Blood Therapeutics stock include Deval L Patrick, Eleanor Ramos, John Schembri, Jung Choi, Kevin P Starr and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, Century Capital Management LLC, OxFORD Asset Management LLP, Tekla Capital Management LLC, PointState Capital LP, ING Groep NV and Fred Alger Management Inc.. Company insiders that have sold Global Blood Therapeutics stock in the last year include Deval L Patrick, Jung Choi, Kevin P Starr and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Global Blood Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Janus Henderson Group PLC, BlackRock Inc., Vanguard Group Inc., PDT Partners LLC, Goldman Sachs Group Inc., Northern Trust Corp and Sphera Funds Management LTD.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eleanor Ramos and John Schembri. View Insider Buying and Selling for Global Blood Therapeutics.

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Global Blood Therapeutics stock can currently be purchased for approximately $27.60.